Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESOPEC adjuvant dendritic cell immunotherapy after CRS-HIPEC for peritoneal mesothelioma
NL-OMON28091Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine in peritoneal mesothelioma, sponsored by Erasmus MC. Primary endpoint: Feasibility of administering adjuvant dendritic cell based immunotherapy after CRS-HIPEC. Started Apr 2018; status: recruiting.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NL-OMON28091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28091.